With over 1 million deaths annually attributed to malaria, an effective vaccine is an urgently needed intervention. However, the various stages of the malaria parasite lifecycle have differing protective immune mechanisms and clinical endpoints, and usually different, often polymorphic, antigens. Trials using an increasing variety of vaccine platforms and antigens are under way in an attempt to achieve this long-awaited goal.